# Contrast-enhanced Ultrasound Evaluation of Chemoembolization

> **NCT02764801** · PHASE3 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 131 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Chemoembolization, Therapeutic

## Interventions

- **DRUG:** Ultrasound contrast agent (Contrast-enhanced ultrasound)
- **DEVICE:** Logiq E9 Scanner (Contrast-enhanced ultrasound)

## Key facts

- **NCT ID:** NCT02764801
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2021-12
- **Final completion:** 2023-02-01
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02764801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02764801, "Contrast-enhanced Ultrasound Evaluation of Chemoembolization". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02764801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*